All these data together suggest that fragments synthesized from the SARS-CoV-2 S protein are capable of immunizing animal model in vivo and they represent therefore a new safer alternative to trigger the inflammatory clinical signs characteristic of COVID-19. The gene discussed is PROS1; the disease is COVID-19.